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Introduction
The increasing availability of molecules designed for tar-
geted treatment of migraine attacks, the triptans, has pro-
duced a proliferation of data regarding the efficacy of such
molecules in relieving migraine pain, accompanying
symptoms and disability. The majority of clinical studies
have been designed to evaluate the efficacy of each com-
pound vs. placebo or vs. sumatriptan, the prototype, i.e.,
the gold standard, of the triptan class, and head-to-head
studies between second-generation triptans are also avail-
able. The number of publications is outstanding and it
would be difficult to go through all of them. Therefore,
information is often sought by reading reviews that sum-
marise data from original articles. However, such a time-
saving learning method, may, somehow, drive the atten-
tion towards certain parameters and obscure other fea-
tures, according to the purpose of a given Author and
therefore provide partial information on a given issue. To
obviate the risk of partial or driven information, the meta-
analytic method has been proposed in order to revise and
analyse data with statistical aids from large numbers of
original trials and to provide objective conclusions.
The present paper should not be considered as a review
as it will not take into consideration the whole literature
concerning triptans, the author not being prone to such a
titanic enterprise. Rather, it will make some examples of
different ways of producing data and try to discuss the
modalities of reading them to avoid misinterpretation and
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Abstract The huge amount of data
regarding triptans in clinical prac-
tice provides a great opportunity to
learn about their efficacy, tolerabil-
ity and adverse events and offers to
the clinician the background for the
best treatment option in any
patient, given that the patient is
suitable for being treated with any
of those compounds. A detailed
clinical history is necessary in
order to make a preliminary selec-
tion of triptan-suitable or -unsuit-
able migraine patients. Among the
former, a secondary selection may
be made, to recognise different
attacks that can be successfully
treated with different triptans,
according to attack presentation
and progression, within the same
patient. Reading single original
articles has become very difficult.
Therefore, data are often presented
in review form, which may be too
partial or oriented. Systematic
reviews or meta-analyses better
serve to comment on data as they
follow an analytic method that is
based upon pooling data from orig-
inal articles and comparing them
using statistical aids.
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misuse of collected information. By definition, the cita-
tion of articles and compounds will not be comprehensive
and will not report any specific result concerning the trip-
tans, as this is not the aim of this commentary. The author
denies any personal or institutional interest in proposing
the following comments and reaffirms that “clinical prac-
tice should reflect scientific evidence blended with clini-
cal experience and expertise” [1, 2].
Clinical trials
The design of clinical trials concerning triptans is basical-
ly very simple. Fig. 1 represents the simplified sketch of a
trial and is based upon six parameters, all being mandato-
ry when preparing the protocol:
Randomisation
It is necessary to assign the compounds in a casual man-
ner to a sufficient number of patients, to avoid any predic-
tion of what compound is assigned to a given patient, to
maintain reliability if any patient will drop out for any rea-
son during the study.
Study design
The study can be planned to compare two active drugs or
an active drug to placebo; in placebo-controlled studies
the patient usually receives two active doses and a place-
bo dose; both patient and researcher are blind to the con-
tent of any single dose preparation. In the triple-blind
design, the monitor is also unaware of the content in each
dose preparation. The researcher is authorised to open the
randomisation code and verify the content of a dose prepa-
ration only in the presence of serious adverse events
occurring during the study that are considered certainly or
probably related to the study.
Statistical analysis
As a general rule, stat aids have to verify the probability
that the event of obtaining success in treating a migraine
attack is related to drug intake and is not casual. Data are
analysed by direct comparison with no need of correction
as no confounding factor is present if proper inclusion and
exclusion criteria are followed (see below). The odds ratio
(OR) is used to define the number of times the event has
occurred and the number of times it has not. In migraine
attack treatment trials the OR expresses the ratio between
active drug-related event and placebo (or second active
drug)-related event. The confidence interval (CI) for dif-
ferences is usually assumed at 95% and expresses the
range values in which 95% of events will fit when repeat-
ing the test.
Inclusion criteria
This parameter has been largely simplified, international
diagnostic guidelines having been available since 1988 [3].
The issue of appropriate clinical diagnosis does not need
further comment. Specific inclusion criteria have to be
applied as general rules in order to reflect the general
migraine population: (i) migraine history of at least 1 year;
(ii) patient age from 18 to 65 years; (iii) presence of 1–6
attacks/month. The protocol should also include a criterion
to warrant an adequate proportion of females and males in
the study group. The latter criterion is not mandatory.
Exclusion criteria
A detailed clinical history of patients should be obtained to
exclude those patients who are not eligible for the study,
i.e., those patients in whom the study drug is contraindi-
cated. Besides, other features have to be disclosed: (i) late-
onset migraine (>50 years); (ii) inability of the patient to
differentiate a migraine attack from other headaches (most
commonly from tension-type headache); (iii) inability to
provide informed consent; (iv) inability or lack of compli-
ance in providing an accurate diary of the attack; (v) use of
other acute treatment compounds that are not allowed con-
comitantly to the study drug; (vi) risk of pregnancy.Fig. 1 Clinical trials in acute migraine treatment
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Endpoints
This is probably the most critical parameter when dealing
with the available literature in this field. In fact, as a gen-
eral rule, patients were instructed to treat their attack
when pain was of moderate intensity. On a 4-point scale
this is defined as a score of 2 (0=absence of pain; 1=mild
pain; 2=moderate pain; 3=severe pain), and within 6–8 h
of pain onset. Initially, the response to drug was evaluated
as an improvement of pain at 2 h post-dose [4], whereas
the pain-free parameter at the same time point has been
introduced more recently [5]. Other parameters to mea-
sure efficacy of study drug on pain, such as Pain Intensity
Difference (PID) or Sum of Pain Intensity Difference
(SPID), are not validated for trial purposes. It is intuitive
that the results from studies that applied different efficacy
measures are not comparable. This also applies when eval-
uating the efficacy of study compounds on accompanying
symptoms. Also, the emerging “the sooner, the better”
treatment option [6] makes the earlier trials less useful to
define the efficacy of certain triptans. It is important to
define the endpoints at the beginning of the study, namely
the primary and the secondary endpoints, and set the sta-
tistical approach and the expected results. Following these
criteria, the analysis will satisfy an ad hoc study design,
i.e., a trial that will serve to verify the hypothesis that has
been proposed. Post hoc analysis should be disregarded
for educational purposes, as it is done to find out whether
the study has produced other information, other than that
for which the original trial was designed. In fact, those
ancillary findings may not be applicable to the population
studied, as patients were initially instructed to carefully
obtain certain data and not others. Therefore, post hoc
analysis might be partial and need further trials for testing
and validating information according to well defined
methods, endpoints and statistical analysis.
The guidelines for clinical trials [5] provide several
recommendations on the above issues. Among them, the
inclusion of placebo is strongly advised. Triptans should
always be compared to placebo, and placebo controls
should be also included when comparing more triptans
with each other, due to the variability of responses to
placebo (from 6% to 41%). Referring to historical place-
bo effects is not suitable. The study should allow a rescue
medication, and this should be permitted at 2 h post-dose,
if necessary. Therefore, the measure of pain-free at 2 h
post-dose should represent the primary endpoint for effi-
cacy evaluation. Another issue concerns the incidence of
relapse, previously named recurrence. It should be clear
that the relapse applies only to those attacks in which pain
was successfully treated (pain-free parameter) at 2 h post-
dose. Table 1 shows a simplified example to calculate
relapse in a head-to-head comparison.
Reviews and meta-analyses
As stated above, reviews are sometimes a useful method
for presenting a few studies within the same publication in
order to focus attention on a certain drug. However, they
simply represent a summary of available data and lack of
methodology or discussion that may enrich the original
data. As an example, Dodick [7] reported a series of
papers regarding efficacy and tolerability of almotriptan.
It is obvious that the studies cannot be pooled together, the
endpoints being different in each trial and involving dif-
ferent methods: comparison with placebo, comparison
with sumatriptan, long-term efficacy open study. Also, a
post hoc analysis concerning the utility of early treatment
(an endpoint that was not chosen prior to any trial indicat-
ed), is described. Ryan et al. [8] summarise data from 3
different studies on the clinical efficacy of frovatriptan vs.
placebo. Besides having different endpoints, the studies
were not available as published original articles and the
Author refers to two abstract citations and to a dose-find-
ing study. Geraud et al. [9] refers to 5 different clinical
studies regarding frovatriptan. Among them there is a
dose-finding study, 2 studies are vs. placebo, 1 is vs.
placebo and sumatriptan 100 mg (with open-label treat-
ment for second and third attack) and 1 is a long-term
open study. The adverse event incidence has been pooled
from the different studies and reported as not different
from placebo. Interestingly, Fisher’s exact test, as per-
Table 1 How to calculate relapses
Compound A Compound B
Number of patients 100 100
Pain-free at 2 hours post-dose 60/100 40/100
Relapse 20/60 20/40
% Relapse 33.3% 50%
The number of relapses is the same in the two groups (compound A- and compound B-treated groups). However, the percent of relapses,
calculated within each pain-free sub-population, is different, ant it may have statistical significance
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formed by Tfelt-Hansen and Steiner [10], shows that the
incidence of side effects in the above studies is extremely
high (p<0.00005 when compared to placebo).
An attempt to apply methodology is made in a post hoc
analysis of 5 different studies comparing rizatriptan with
sumatriptan (25, 50 or 100 mg) and naratriptan on the nau-
sea symptom of migraine [11]. Although the trials share
similar study design, the endpoints chosen prior to trials,
namely relief of pain and associated symptoms, did not
focus on the nausea itself and it is possible that patients
did not report mild nausea (either as an accompanying
symptom that has improved following attack treatment or
as an adverse event to the treatment itself) after being
pain-free.
As said above, systematic reviews and meta-analyses
are of better use because they statistically analyse very
large numbers of trials (hence, a very large number of
attacks, either on active drug or placebo) to obtain:
- higher statistical power;
- better estimation of drug efficacy;
- population sub-groups;
- new hypotheses to be verified.
In 2001, Ferrari et al. [12] proposed a meta-analysis on
53 acute migraine treatment trials including 24,089
patients. All trials were randomised (placebo-controlled),
cross-over and double blind. Cumulative data for suma-
triptan 100 mg (gold standard) and for all different trip-
tans were obtained from international publications and
registration packages (according to Good Clinical Practice
method). The Authors declared no conflict of interest in
their study, i.e., the study was not commissioned or spon-
sored by any pharmaceutical company. The latter declara-
tion has an outstanding value in this context, as it means
that the Authors qualified themselves as independent from
any biased interpretation of the results.
The work takes many clinical parameters into consid-
eration in order to propose the final list of triptans accord-
ing to the best efficacy+tolerability profile. Efficacy para-
meters were:
- headache response at 2 h post-dose: pain reduction of
at least two points in the “0–3” scale (see above), i.e.,
moderate pain to absence of pain, or severe pain to
mild or absent;
- pain-free at 2 h post-dose;
- headache recurrence (or relapse);
- sustained pain-free (no recurrence within 24 h, no need
of rescue medication, no need of second dose);
- intra-individual consistency (i.e., the drug is consis-
tently effective over multiple attacks);
- adverse events.
As said above, the effects of inactive compound
(placebo) accounts for up to 41% of good responses.
Therefore, an interesting way of presenting and compar-
ing data is represented by the therapeutic gain (TG),
which is calculated by subtracting the number of attacks
that were successfully treated with placebo to the number
of attacks that were successfully treated by active drug.
The same applies to the therapeutic harm (TH) regarding
the occurrence of side effects due to placebo or active
drug [13]. The reciprocal of those values is represented by
the number needed to treat (NNT) and the number needed
to harm (NNH) values, which express the number of
patients who have to receive the drug to obtain one suc-
cessfully treated attack and the number of patients who
have to be treated to get one side effect. It is intuitive that
the best compound has a very low NNT and a very high
NNH value. Accordingly, the best compound has the high-
est TG and the lower TH. Ferrari et al. [12] reported the
data regarding the above clinical parameters using both
the comparison between absolute values and the TG and
TH values. Interestingly, the large number of patients re-
evaluated in this analysis make some issues even more
evident and raises questions that need to be evaluated in
more detailed fashion.
For instance, the definition of recurrence (or relapse)
applies to pain that recurs within 24 h. Usually subjects
are instructed to treat pain when the intensity is moderate
or severe. The question is: what to do if pain is mild (score
1 on a 0–3 scale)? There are no indications to answer this
question and maybe they will come from further studies
regarding early treatment, as suggested by certain clinical
Fig. 2 Cross-linking tolerability and efficacy data is necessary for
choosing the best triptan option and the “ideal triptan” (black box)
should be located at the top level of tolerability and the highest
value of efficacy. As no triptan has yet reached such a position, the
choice should be made according to scientific data and to patient
preference as well. The bottom histogram shows patient preference
as reported by Lanteri-Minet et al. [15]: (A) pain free; (B) no
relapse; (C) fast action; (D) no adverse events; (E) relief of accom-
panying symptoms
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studies [6]. Another issue concerns the consistency of
response. The trend is that the percent of either the
headache response and the pain-free decreases over the
attacks, i.e., the percent efficacy is lower in the second and
third attack treated. The placebo effect decreases even
more in multiple attacks, therefore, the “placebo problem”
is not solved, and it makes the across-patient and intra-
patient variability still too high. Finally, the evaluation of
adverse events should take into consideration the possibil-
ity that some of them are actually accompanying symp-
toms rather than side effects. Unfortunately, diagnostic
guidelines require the presence of nausea and/or vomiting
and phonophobia and photophobia as accompanying
symptoms in migraine attacks. There is no attention on
other symptoms and therefore they are not recorded as
such during clinical trials. Instead, they are considered as
drug adverse events. Patients should be preliminarily
asked during clinical interview to describe any other
symptoms, although not required for diagnosis, in order to
subtract them from those occurring after medication.
Enriching clinical trials with this information may help
for better choice of treatment and better definition of
adverse events and accompanying symptoms as well.
The analysis proposed by Belsey [14], although
declared as sponsored by an educational grant by a phar-
maceutical company, provides analytic data from 28 effi-
cacy studies and 35 tolerability studies (25 studies are
coincident) that were chosen according to a validity index.
All studies were randomised, placebo-controlled and dou-
ble blind. Data are expressed as TG, TP, NNT and NNH
values. The information obtained are comparable to those
from the meta-analysis by Ferrari et al. [12]. As Belsey
states, “this kind of analysis provides a clinically intuitive
treatment choice and the methodology may be applied to
different therapeutic areas”. The method offers the oppor-
tunity of tailoring therapy to any single patient according
to his/her needs, expectations and preferences (Fig. 2)
[15]. However, in Tfelt-Hansen’s opinion, although com-
prehensive, meta-analyses have the limitation of different
data sources, well performed head-to-head comparison
studies being the best scientific approach to obtain valu-
able clinical data [16].
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